DigestRedComo funciona
Red
/
Empresas
Mi
No verificado

Mirum Pharmaceuticals, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosMercado de valoresSalud

71 Comunicados de prensa

Ver todos los comunicados de prensa
29/04/2026
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Biotecnología
Farmacéutica
Salud
Mirum Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
Fuente
Mirum Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
27/04/2026
Industria
Salud
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
Fuente
Mirum Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
27/04/2026
Industria
Salud
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
Fuente
Mirum Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
13/04/2026
Mercado laboral
Finanzas
Mercado de valores
Biotecnología
Farmacéutica
Salud
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fuente
Mirum Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
16/03/2026
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Industria
Mirum Pharmaceuticals Completes Enrollment in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Additional Rare Cholestatic Liver Diseases
Fuente
Mirum Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
12/03/2026
Mercado de valores
Finanzas
Salud
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fuente
Mirum Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
05/03/2026
Industria
Salud
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus
Fuente
Mirum Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
25/02/2026
Web y redes sociales
Telefonía
Mercado de valores
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update
Fuente
Mirum Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
23/02/2026
Eventos
Web y redes sociales
Salud
Farmacéutica
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Fuente
Mirum Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
18/02/2026
Salud
Biotecnología
Sanidad
Ciencia
Farmacéutica
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026
Fuente
Mirum Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0